OPKO Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by OPKO Health, Inc. on February 9, 2017. The filing reports a corporate governance event regarding the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The primary material change reported is the appointment of Richard M. Krasno, Ph.D., as a new director effective February 9, 2017. Dr. Krasno was also appointed to the Audit Committee and Compensation Committee. The Board determined that Dr. Krasno is independent under applicable SEC and Nasdaq rules.
Compensation and Governance Details
- Stock Options: Dr. Krasno received a grant of 40,000 stock options under the Company's 2016 Equity Incentive Plan.
- Exercise Price: The options have an exercise price of $8.10, based on the closing stock price on February 9, 2017.
- Additional Compensation: Dr. Krasno will receive standard compensation for non-employee directors and has entered into a standard director indemnification agreement.
- Background: Dr. Krasno has prior experience as executive director of the William R. Kenan, Jr. Charitable Trust, president of the Monterey Institute of International Studies, and director of the University of North Carolina Health Care System.
Outlook and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary on future performance, or specific risk factors beyond standard governance disclosures.
Key Facts for Investor Verification
- Verify the independence status of the newly appointed director, Richard M. Krasno, Ph.D.
- Confirm the terms of the 40,000 stock option grant, including the $8.10 exercise price and vesting schedule.
- Review Dr. Krasno's current board affiliations (Ladenburg Thalmann, Castle Brands, Inc., and BioCardia, Inc.) for potential conflicts of interest.
- Check the Company's 2016 Equity Incentive Plan to ensure the grant was within authorized limits.